Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription 01.09.2025 3 BMJ 1 J Immunol 1 J Infect 3 JAMA 2 MMWR Morb Mortal Wkly Rep 2 Nat Med 1 Pediatr Infect Dis J 1 Pediatr Rev 4 PLoS One 1 Science 27 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMJ

1. IACOBUCCI G
   Chickenpox vaccine to be offered to children in England.
   BMJ. 2025;390:r1828.
   PubMed        
   
   
2. TANNE JH
   CDC director is forced out over vaccine policy, and four senior scientists resign.
   BMJ. 2025;390:r1831.
   PubMed        
   
   
3. BOWIE K
   Shingles vaccine will be offered to more immunosuppressed adults in England.
   BMJ. 2025;390:r1816.
   PubMed        
   
   

   
   J Immunol

4. HANSEN SG, Schell JB, Marshall EE, Ojha S, et al
   Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIV.
   J Immunol. 2025 Feb 27:vkaf104. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect

5. VALENTINA M, Giulia M, Eleonora C, Alessandro C, et al
   Humoral and T-Cell Responses Following MVA-BN Booster Vaccination Against Mpox Virus Clades Ib and IIb.
   J Infect. 2025 Aug 25:106602. doi: 10.1016/j.jinf.2025.106602.
   PubMed        
   
   

   
   JAMA

6. ANDERER S
   HHS Ends mRNA Vaccine Development.
   JAMA. 2025 Aug 29. doi: 10.1001/jama.2025.11013.
   PubMed        
   
   
7. ANDERER S
   CDC: Kindergarten Vaccine Exemptions Rise.
   JAMA. 2025 Aug 29. doi: 10.1001/jama.2025.11015.
   PubMed        
   
   
8. SILVERMAN A, Walsh R, Santoro JD, Thomas K, et al
   Influenza-Associated Acute Necrotizing Encephalopathy in US Children.
   JAMA. 2025 Jul 30:e2511534. doi: 10.1001/jama.2025.11534.
   PubMed         Abstract available
   
   

   
   MMWR Morb Mortal Wkly Rep

9. MOULIA DL, Link-Gelles R, Chu HY, Jamieson D, et al
   Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025.
   MMWR Morb Mortal Wkly Rep. 2025;74:508-514.
   PubMed         Abstract available
   
   
10. GROHSKOPF LA, Blanton LH, Ferdinands JM, Reed C, et al
    Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025-26 Influenza Season.
    MMWR Morb Mortal Wkly Rep. 2025;74:500-507.
    PubMed         Abstract available
    
    

    
    Nat Med

11. O'LEARY K
    Aluminum in childhood vaccines not linked to chronic diseases.
    Nat Med. 2025 Aug 29. doi: 10.1038/d41591-025-00055.
    PubMed        
    
    
12. SHI W, Wohlwend J, Wu M, Barzilay R, et al
    Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model.
    Nat Med. 2025 Aug 28. doi: 10.1038/s41591-025-03917.
    PubMed         Abstract available
    
    

    
    Pediatr Infect Dis J

13. GWAK E, Choe SA, Kim K, Bolormaa E, et al
    Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents.
    Pediatr Infect Dis J. 2025 Aug 27. doi: 10.1097/INF.0000000000004954.
    PubMed         Abstract available
    
    

    
    Pediatr Rev

14. ALLEN HD, Puri K, Zenel JA
    Recognizing a Few of the Vaccine Preventable Diseases.
    Pediatr Rev. 2025;46:467-481.
    PubMed        
    
    

    
    PLoS One

15. FISMAN DN, Amoako A, Simmons A, Tuite AR, et al
    Correction: Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority.
    PLoS One. 2025;20:e0330965.
    PubMed         Abstract available
    
    
16. KASSA B, Mohammed A, Wassie GT
    Parents' acceptance of human papilloma virus vaccination for their daughters in adet town, North Gojjam zone, Northwest Ethiopia: A mixed method study.
    PLoS One. 2025;20:e0330911.
    PubMed         Abstract available
    
    
17. PUGGINA A, Marijam A, Cailloux O, Vicentini M, et al
    Physician knowledge, attitudes, and perceptions of respiratory syncytial virus in older adults: A cross-sectional survey in Germany and Italy.
    PLoS One. 2025;20:e0330763.
    PubMed         Abstract available
    
    
18. KARACHALIOU PRASINOU A, Trotter C
    Modelling of strategies for the introduction and routine use of multivalent meningococcal conjugate vaccines (MMCVs) in the African meningitis belt.
    PLoS One. 2025;20:e0330627.
    PubMed         Abstract available
    
    

    
    Science

19. BERKLEY S
    Unraveling the arc of vaccine progress.
    Science. 2025;389:eaea7053.
    PubMed         Abstract available
    
    

    
    Vaccine

20. MORGAN JC, Kornides ML, Lee J, Fishman J, et al
    Different vaccination debunking interventions: a randomized, controlled experiment estimating "backfiring" and positive effects.
    Vaccine. 2025;62:127463.
    PubMed         Abstract available
    
    
21. AKSUCU G, Caglar S
    Effects of telehealth during pregnancy on childhood vaccine attitudes and timeliness: A randomized controlled trial.
    Vaccine. 2025;63:127678.
    PubMed         Abstract available
    
    
22. HATZL S, Posch F, Schulz E, Uhl B, et al
    Altered immune responses to mRNA vaccination against SARS-COV-2 are characterized by an impaired cross-talk between humoral and T-cellular immune compartments in patients with hematologic diseases.
    Vaccine. 2025;63:127666.
    PubMed         Abstract available
    
    
23. GAO RY, Hu T, Taylor AW, Lacey R, et al
    Assay for rapid quantification of capped and tailed intact mRNA.
    Vaccine. 2025;61:127339.
    PubMed         Abstract available
    
    
24. ANEZ G, McGarry A, Woo W, Kotloff KL, et al
    Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).
    Vaccine. 2025;61:127362.
    PubMed         Abstract available
    
    
25. WANG Y, Lu G
    Global, regional, and national epidemiology of pertussis in children from 1990 to 2021.
    Vaccine. 2025;61:127378.
    PubMed         Abstract available
    
    
26. SCHUTT CR, Birol D, Lu X, Yamasaki S, et al
    The presenting HLA determines fidelity of SARS-CoV-2 spike protein epitope prediction.
    Vaccine. 2025;61:127381.
    PubMed         Abstract available
    
    
27. REYBURN R, Russell FM, Munywoki PK, Franzel L, et al
    Designing effectiveness and impact studies for respiratory syncytial virus immunisation in low- and middle-income countries.
    Vaccine. 2025;61:127397.
    PubMed         Abstract available
    
    
28. CHOQUE-GUEVARA R, Poma-Acevedo A, Montesinos-Millan R, Sernaque-Aguilar Y, et al
    Chimeric designs of rabies virus glycoprotein G enhance baculovirus pseudotyping and immunogenicity in mice: influence of the transmembrane domain and a flexible linker.
    Vaccine. 2025;61:127404.
    PubMed         Abstract available
    
    
29. MCDONALD JU, Hosken NA, Engelhardt OG
    Assessing commutability of the first WHO International Standard for antiserum to respiratory syncytial virus.
    Vaccine. 2025;61:127430.
    PubMed         Abstract available
    
    
30. ARAKAWA T, Uefuji H, Tamaki Y, Oogai S, et al
    B subunit of the type 2 Shiga toxin e variant (Stx2e) bundled by a five-stranded alpha-helical coiled coil protects piglets from porcine edema disease.
    Vaccine. 2025;61:127140.
    PubMed         Abstract available
    
    
31. XIANG W, Pan B, Hao Y, Wang F, et al
    Chimeric virus-like particles replacing the loop on the surface of VP60 from rabbit hemorrhagic disease virus (RHDV) provide protection against two serotypes of RHDV.
    Vaccine. 2025;61:127427.
    PubMed         Abstract available
    
    
32. LI G, Marchevsky NG, Macaulay G, Aley P, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
    Vaccine. 2025;62:127597.
    PubMed         Abstract available
    
    
33. PATEL C, Wang X, Giles M, Burns P, et al
    The role of serological testing for vaccination with a focus on immunocompromised patients: a synthesis of current evidence.
    Vaccine. 2025;63:127659.
    PubMed         Abstract available
    
    
34. BEAULIEU A, LaMonaca K, Higginbottom J, Foster J, et al
    Utilizing the Program Impact Pathways framework for improving COVID-19 vaccine confidence and uptake: demonstrations of multi-sector collaboration from two geographies in Connecticut.
    Vaccine. 2025;60 Suppl 1:127623.
    PubMed         Abstract available
    
    
35. BREWER SK, Lewis RM, Querec TD, Unger ER, et al
    Evaluation of possible human papillomavirus (HPV) type replacement after vaccine introduction, overall and by race/ethnicity, United States.
    Vaccine. 2025;62:127576.
    PubMed         Abstract available
    
    
36. BARLOW M, Flanagan S, Ghosh I, Carter J, et al
    Offering Hepatitis B vaccination to vulnerable populations: How can we plug the gaps?
    Vaccine. 2025;63:127639.
    PubMed        
    
    
37. ALMUKHTAR S, McWhirter N, Mendiola A, Samuel S, et al
    Exploring lingering COVID-19 vaccine hesitancy in three diverse U.S. states: Alabama, Illinois, and Texas.
    Vaccine. 2025;60 Suppl 1:127664.
    PubMed         Abstract available
    
    
38. WARD JK, Youssef R, Peretti-Watel P
    Different vaccines, different trust issues? Disentangling the effect of trust in various institutions using dominance analysis.
    Vaccine. 2025;63:127668.
    PubMed         Abstract available
    
    
39. HOTEZ PJ
    COVID-19 vaccinations in America: Don't forget long COVID and the post-acute sequelae.
    Vaccine. 2025;63:127676.
    PubMed        
    
    
40. MUTHURAMAN KR, Boonyakida J, Matsuda M, Suzuki R, et al
    Comparative immunogenicity study of quartet and bifurcated tetravalent dengue virus envelope domain III displayed virus-like particle vaccine candidates in BALB/c mice.
    Vaccine. 2025;63:127670.
    PubMed         Abstract available
    
    
41. VASILEV K, Puente-Massaguer E, Hoxie I, Bushfield K, et al
    Innate and T-cellular immune responses to sequential vaccination with chimeric hemagglutinin split influenza virus vaccines in mice.
    Vaccine. 2025;63:127626.
    PubMed         Abstract available
    
    
42. MARZO E, Guirado E, Taberner E, Castanyer S, et al
    A new method for testing avian metapneumovirus vaccine efficacy: Evaluation of tracheal ciliary activity after a challenge.
    Vaccine. 2025;63:127641.
    PubMed         Abstract available
    
    
43. COSGROVE S, Hider P, Anglemyer A, Walls T, et al
    HPV vaccination in Aotearoa New Zealand: Impact of a school-based program on adolescent vaccine coverage.
    Vaccine. 2025;63:127637.
    PubMed         Abstract available
    
    
44. FU JYL, Syed Omar SF, Rajasuriar R, Kukreja A, et al
    Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia.
    Vaccine. 2025;63:127657.
    PubMed         Abstract available
    
    
45. KITAMURA N, Tomo Y, Okuyama M, Ueda K, et al
    COVID-19 vaccine effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in Japan.
    Vaccine. 2025;63:127656.
    PubMed         Abstract available
    
    
46. CHEONG C, Choi WS, An JE, Cho J, et al
    Cost-effectiveness of including herpes zoster vaccines into the national immunization program in the Republic of Korea.
    Vaccine. 2025;63:127648.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.